NCT02836548 is a phase I/II ongoing clinical trial evaluating the efficacy and side effects of BCL-2 inhibitor Navitoclax in conjunction with dabrafenib and trametinib to target the apoptosis regulator BCL-2, which is typically overexpressed in melanoma[132]. The gene discussed is BCL2; the disease is melanoma.